Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle
K Khanna, SK Kohli, R Kaur, A Bhardwaj, V Bhardwaj… - Phytomedicine, 2021 - Elsevier
Current scenario depicts that world has been clenched by COVID-19 pandemic. Inevitably,
public health and safety measures could be undertaken in order to dwindle the infection …
public health and safety measures could be undertaken in order to dwindle the infection …
In Vitro and in Vivo Biological Investigations of Camphene and Its Mechanism Insights: A Review
ABSTRACT Camphene (C10H16) also-called2, 2-dimethyl-3-methylidenebicyclo [2.2. 1]
heptane is a volatile compound belonging to the terpenoid family, in particular to the group …
heptane is a volatile compound belonging to the terpenoid family, in particular to the group …
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19) …
Background Currently no effective antiviral therapy has been found to treat COVID-19. The
aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical …
aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical …
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
Objectives Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against
hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents …
hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents …
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with …
H Abbaspour Kasgari, S Moradi… - Journal of …, 2020 - academic.oup.com
Background New therapeutic options are urgently needed to tackle the novel coronavirus
disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate …
disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate …
Evaluating anti-coronavirus activity of some phosphoramides and their influencing inhibitory factors using molecular docking, DFT, QSAR, and NCI-RDG studies
K Gholivand, F Mohammadpanah, M Pooyan… - Journal of Molecular …, 2022 - Elsevier
The recent prevalence of coronavirus disease in 2019 (COVID-19) has triggered
widespread global health concerns. Antiviral drugs based on phosphoramides have …
widespread global health concerns. Antiviral drugs based on phosphoramides have …
The nanocomposites designs of phytomolecules from medicinal and aromatic plants: promising anticancer-antiviral applications
A Kaplan - Beni-Suef University Journal of Basic and Applied …, 2022 - Springer
Background Nowadays, researchers are moving toward a herbal approach to cancer
treatment because of the harmful effects of synthetic anti-tumor drugs. The evaluation of …
treatment because of the harmful effects of synthetic anti-tumor drugs. The evaluation of …
Molecular docking as a potential approach in repurposing drugs against COVID-19: A systematic review and novel pharmacophore models
M Fadlalla, M Ahmed, M Ali, AA Elshiekh… - Current Pharmacology …, 2022 - Springer
Abstract Purpose of Review This article provides a review of the recent literature related to
the FDA-approved drugs that had been repurposed as potential drug candidates against …
the FDA-approved drugs that had been repurposed as potential drug candidates against …
Novel Drug Design for Treatment of COVID‐19: A Systematic Review of Preclinical Studies
Background. Since the beginning of the novel coronavirus (SARS‐CoV‐2) disease
outbreak, there has been an increasing interest in discovering potential therapeutic agents …
outbreak, there has been an increasing interest in discovering potential therapeutic agents …
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis
Background The combination of sofosbuvir and daclatasvir has a well-established safety
profile and improves clinical outcomes in HCV patients. In silico and in vitro studies suggest …
profile and improves clinical outcomes in HCV patients. In silico and in vitro studies suggest …